• Info
  • Significant Ownership

Significant Ownership of Farallon Capital Partners, L.P.

Signature - Title
/s/ Hannah E. Dunn - Hannah E. Dunn, Managing Member of its General Partner
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Farallon Capital Partners, L.P..

Notify me when Farallon Capital Partners, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Farallon Capital Partners, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PTGX Protagonist Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares") 10% $545,701,455 +$25,461,794 6,248,013 +4.9% Dapice Joshua J. 31 Dec 2025
BEAM Beam Therapeutics Inc. Common Stock, par value $0.01 per share (the "Shares") 10% $281,132,248 +$4,681,243 10,141,856 +1.7% Dapice Joshua J. 31 Dec 2025
NERV Minerva Neurosciences, Inc. Common Stock, $0.0001 par value per share (the "Shares") 10% $18,250,213 4,539,854 0% Dapice Joshua J. 31 Dec 2025
LQDA Liquidia Corporation Common Stock, par value $0.001 per share (the "Shares") 9.9% $316,810,991 +$3,308,640 8,656,038 +1.1% Dapice Joshua J. 31 Dec 2025
BBNX Beta Bionics, Inc. Common Stock, $0.0001 par value per share (the "Shares") 9.9% $88,211,589 +$3,544,640 4,379,920 +4.2% Dapice Joshua J. 31 Dec 2025
ENTA ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (the "Shares") 9.8% $44,421,914 +$11,174,622 2,816,862 +34% Dapice Joshua J. 31 Dec 2025
TNGX Tango Therapeutics, Inc. Common stock, par value $0.001 per share (the "Shares") 9.7% $90,358,800 +$13,440,000 10,757,000 +17% Dapice Joshua J. 30 Sep 2025
AGIO AGIOS PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (the "Shares") 8.8% $146,117,182 -$14,583,696 5,159,505 -9.1% Dapice Joshua J. 31 Dec 2025
CRNX Crinetics Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (the "Shares") 8.5% $373,521,762 +$111,673,450 8,024,098 +43% Dapice Joshua J. 31 Dec 2025
CATX Lantheus Holdings, Inc. Common Stock, par value $0.01 per share (the "Shares") 8.2% +$6,689,559 5,427,479 +56% Dapice Joshua J. 31 Dec 2025
ASMB Assembly Biosciences, Inc. Common Stock, par value $0.001 per shares (the "Shares") 7.8% $38,963,707 +$2,763,919 1,227,590 +7.6% Dapice Joshua J. 31 Dec 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share (the "Shares") 7.5% $1,499,170,464 +$137,025,822 14,596,149 +10% Dapice Joshua J. 31 Dec 2025
SVRA Savara Inc. Common Stock, par value $0.001 per share (the "Shares") 6.9% $90,445,500 -$19,831,599 15,000,000 -18% Dapice Joshua J. 31 Dec 2025
MEHCQ 23andMe Holding Co. Class A Common Stock, par value $0.0001 per share 6.2% $3,876,269 1,270,908 Dapice Joshua J. 13 Jun 2025
EXEL EXELIXIS, INC. Common Stock, par value $0.001 per share (the "Shares") 5.9% $650,216,205 -$121,107,140 15,709,500 -16% Dapice Joshua J. 01 Jan 2026
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share (the "Shares") 5.9% $234,502,668 +$16,316,300 2,342,684 +7.5% Dapice Joshua J. 31 Dec 2025
TYRA Tyra Biosciences, Inc. Common Stock, $0.0001 par value per share (the "Shares") 5.6% $93,723,285 2,984,818 Dapice Joshua J. 12 Feb 2026
ARMK Aramark Common Stock, Par Value $0.01 per share (the "Shares") 4.9% $562,813,955 -$145,824,331 12,899,701 -21% Dapice Joshua J. 30 Jun 2025
NYT The New York Times Company Class A Common Stock, par value $0.10 per share (the "Shares") 3.5% $314,022,385 -$190,445,639 5,609,546 -38% Dapice Joshua J. 30 Jun 2025
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share (the "Shares") 3.4% $12,130 221,027 Dapice Joshua J. 31 Dec 2024
ANNA AleAnna, Inc. Class A common stock, par value $0.0001 per share (the "Shares") 2.6% $12,671,224 1,068,400 Dapice Joshua J. 31 Dec 2024
ELEV Elevation Oncology, Inc. Common Stock, Par Value $0.0001 per share (the "Shares") 0% $0 -$1,305,168 0 -100% Farallon Capital Partners, L.P. 31 Mar 2025

Schedules 13D/G Reported by Farallon Capital Partners, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.